General anaesthetics gain access to all parts of the body and thus interact at the molecular level with every component in the biosphere including lipids, proteins and even oligosaccharides. 43 In order for any of these interactions to cause the various physiological changes that result in general anaesthesia, or its many side-effects, they must occur at clinically relevant concentrations and they must cause a change in the function of the system. Thus, in order to approach the molecular mechanisms of action of general anaesthetics it is necessary to understand both the forces that govern how anaesthetics interact with their sites of action and the mechanisms available to transform these interactions into functional outcomes.
Physicochemical indicators of the nature of the anaesthetic site
Early workers rejected the lock and key model for ligands binding to proteins because the diverse structures of general anaesthetics could not possibly ®t a single lock. Instead they adopted a physicochemical approach, attempting to de®ne the nature of that site by seeking correlations between general anaesthetic potency in vivo and various physical properties, particularly those de®ning interactions between anaesthetics and some other substance. If a poor correlation is observed, as is the case for example with aqueous solubility, one concludes that the nature of the site of pharmacological action is different. The well-known correlation between anaesthetic potency and olive oil solubility reigned as the most powerful in pharmacology until the discovery of opiate receptor binding assays 70 yr later. Olive oil was chosen to mimic the lipoids of the cell, 40 49 but after half a century a more systematic approach was introduced that examined solvents on the basis of their solubility parameter. 47 This parameter increases with solvent polarity from a low value of 6 for hydrocarbons. General anaesthesia correlates best with solvents with solubility parameters of 10±11, 45 implying some polarity at the site of action. However, different pharmacological actions of anaesthetics were found to occur at sites of different solubility parameter. 47 For example, the convulsant gases appear to interact at a site of lower solubility parameter than anaesthetic gases. 11 If there are several sites for anaesthetic actions that differ in polarity, the theory would predict that general anaesthetics of varying polarity would distribute amongst them selectively; the more polar ones favouring the more polar sites, for example. This predicts that the spectrum of action of each anaesthetic will depend on its polarity, and that agents of similar polarity will have similar spectrums of action.
One of the assumptions underlying the physicochemical approach is that when half of a group of animals is anaesthetized with any volatile agent, they are in an isonarcotic state in which their physiology is identical. This is the unitary hypothesis and it is questioned by the above notion that there may be a number of anaesthetic sites exhibiting a spectrum of polarity. 55 
Recent evidence for multiple sites
Two lines of recent research emphasize these concerns. First, subanaesthetic concentrations of volatile anaesthetics suppress learning. This action may occur at a site distinct from that causing general anaesthesia because a group of non-anaesthetic agents (termed non-immobilizers) can suppress learning in animals at predicted concentrations but are incapable of producing full anaesthesia as measured by immobility in response to a painful stimulus. The interpretation is that suppression of learning and immobility are two effects of anaesthetics that are mediated by different sites. Non-immobilizers are apolar whereas most full general anaesthetics have polar character. Learning suppression then occurs at a less polar site than that producing anaesthesia or immobility. 24 The non-immobilizers lack action at the GABA A receptor, which has long been regarded as a common target for all general anaesthetics, 74 but they do act on acetylcholine receptors, 27 as do most volatile general anaesthetics.
Second, it has now emerged that two clinically used apolar general anaesthetics, xenon 28 and cyclopropane, 55 do not interact with GABA A receptors. Whilst one must be cautious about drawing conclusions until a wider range of subunits has been examined, nonetheless these ®ndings are a challenge to the established view that action on GABA A receptors is central to an agent's ability to produce general anaesthesia. 74 These gases do, however, inhibit acetylcholine and NMDA receptors. Might these latter receptors have sites of lower polarity than those on GABA A receptors? While the location of anaesthetic sites on these receptors is not unambiguously established, the outer end of the cation channel of the acetylcholine receptor is lined with hydrophobic residues, whereas that in the GABA A receptor exhibits more polarity. One interpretation of the facts that are currently available to us is that general anaesthesia can be produced by agents acting at several targets to reduce the overall level of excitability. General anaesthetics certainly act on the superfamily of receptors that includes GABA A , glycine, nicotinic acetylcholine and serotonin 5HT 3 receptors and on the structurally unrelated NMDA receptors. The ®rst two are inhibitory and the other three excitatory. General anaesthetics tend to enhance the activity of inhibitory receptors and inhibit the activity of excitatory receptors. All the more polar anaesthetics act on the inhibitory receptors and on acetylcholine receptors, whereas the less polar ones act on acetylcholine and NMDA receptors. A working hypothesis might be that more polar general anaesthetics enhance inhibition at GABA A and glycine receptors and inhibit excitation at acetylcholine receptors, whereas the apolar general anaesthetics make up for their lack of action on GABA A receptors by further inhibiting excitation at NMDA receptors.
An alternative explanation is that none of these receptor types is central to general anaesthesia and that the true target has yet to be discovered. Certainly genetic studies on anaesthesia in Caenorhabditis elegans have not implicated any of these ligand-gated ion channels. 14 61 Nonetheless, the ligand-gated ion channels are acted upon by clinical concentrations of general anaesthetics and these interactions must give rise to some physiological sequelae. Working out the molecular basis of general anaesthetic action on these channels is a necessary step in understanding the basis of selectivity between targets and is a start down the road to rational drug design.
The anaesthetic-sensitive ligand-gated superfamily of ion channels
Structure
The dif®culties of applying x-ray crystallography and NMR to membrane proteins, let alone ones as large as the ligandgated superfamily of ion channels, means that there is no direct and de®nitive evidence at the atomic level for anaesthetic binding sites on them. Such detailed evidence is only found on the readily crystallizable soluble proteins that we will consider later in this review.
The ligand-gated ion channels are thought to have ®ve subunits, each contributing the second of four transmembrane helices (M2) to lining a pore along a central axis 67 ( Fig. 1A ). This picture is based largely on the acetylcholine receptor (nAcChoR), which has a unique advantage over the other members of this superfamily. The subtype found in Torpedo electroplaque membranes has a speci®c activity 10 000 times higher than that of any other member. Because of its abundance, biochemical and structural studies have been performed on the nAcChoR and the results extrapolated by homology to design experiments on other members of the family. The overall structure of the nAcChoR in the resting, open and desensitized conformations has been studied by cryoelectron microscopy to a resolution suf®-cient to reveal some of the secondary structure. The ionconducting pore can be seen to be lined by a-helices but the secondary structure of the remaining transmembrane structures remains speculative (Fig. 1B) .
A molluscan acetylcholine binding protein has been crystallized. Its sequence is highly homologous with the N-terminal, pre-M1 part of the a-subunit of the nAcChoR. 6 (For a ®gure, see Trudell. 66 ) This structure con®rms other evidence indicating that the agonist sites are located at the interfaces between subunits. 9 
Allosteric behaviour
Many proteins can coexist in a number of conformations of similar energy. The most highly populated conformation will be the one with lowest free energy. So ®nely poised are these conformations that binding of a small ligand selectively to a minor conformation may stabilize it suf®ciently that it now becomes the predominant conformation. The ligand-gated ion channels of receptors are normally in a resting non-conducting state, which has low af®nity for agonist, in equilibrium with a small proportion in the desensitized state, which has high af®nity for agonist but does not conduct when stimulated. 17 Upon binding two agonist molecules of molecular weight~10 2 Da, thesẽ 250 kDa receptors convert to the conducting conformation in less than a millisecond. In the continuing presence of agonist, a third conformation slowly accumulates. This is the desensitized conformation, which is non-conducting. Table 1 illustrates this for the acetylcholine receptor. 9 Structural and kinetic evidence for the acetylcholine 67 and the GABA A 32 receptor suggest that all conformational changes involve a rearrangement of the subunits relative to each other, often involving slight rotations. These are particularly apparent in the ion-conducting pore, or channel, on the central axis of symmetry where all ®ve subunits meet. That general anaesthetics act allosterically on these channels is supported by a variety of evidence.
Effects of general anaesthetics
Studies focused on these ion channels have led to signi®cant advances in our understanding of how general anaesthetics act. However, whilst one might expect that individual ion channels would have a simpler pharmacology than intact animals, it turns out paradoxically that even on a single protein general anaesthetics exert multiple effects.
The major actions of general anaesthetics on the ligandgated ion channel superfamily are as follows. First, on the cation channels most, but not all, general anaesthetics inhibit agonist-induced ion currents, depressing the maximum of the agonist concentration±response curve without shifting its midpoint, as expected for insurmountable action. Inhibition may also occur on the anion channels (GABA A , glycine) but only at much higher concentrations. 50 Second, general anaesthetics cause a leftwards shift in the agonist concentration±response curve to lower concentrations. This occurs in the anion channels and with some of the smaller agents in the cation channels. Third, many general anaesthetics enhance agonist-induced desensitization in all members of the family. Fourthly, intravenous agents bind to discrete sites which are allosterically linked to the agonist site. 48 Many of these actions are elaborated upon by Dilger 17 and here we will emphasize only mechanistic information. Our working model will be that there are a number of different anaesthetic sites on this superfamily of receptors, and that the relative af®nity of these sites for general anaesthetics varies both between members of the family and between conformational states of each receptor.
Evidence for allosteric anaesthetic binding sites
Binding studies The high speci®c activity of the nAcChoR in Torpedo membranes made it possible to directly determine by pharmacological binding assays that there is a [ 14 C]barbiturate binding site on the acetylcholine receptor. This remains the only demonstration of its type and it is worth considering in some detail because it illustrates the principle of allosteric action. The enantiomers of pentobarbital bind stereoselectively to nAcChoR membranes from Torpedo. 57 About half the binding is displaceable. Of the The nature of sites of general anaesthetic action various proteins available in these membranes, the barbiturate bound to the nAcChoR, addition of agonist reducing the amount of binding. This was neither a competitive nor a non-speci®c interaction because the highly speci®c competitive antagonist a-bungarotoxin had no effect on barbiturate binding but prevented the effect of agonist. 18 When [ 3 H]acetylcholine was titrated causing progressively more of the receptors to be driven into the desensitized state, [ 14 C]amobarbital binding decreased in parallel with the state change. Thus, amobarbital binds with higher af®nity to the resting than to the desensitized state, whereas acetylcholine binds with higher af®nity to the desensitized state (Fig.  2) . It follows that the two binding sites are coupled by an allosteric interaction. Such an interaction could lead to either an increase or a decrease in binding of the allosteric ligand. In this case a decrease is seen, often called a negative heterotropic interaction. The strength, and indeed even the direction, of this allosteric interaction can depend on the ligand's structure. For example, secobarbital bound with equal af®nity to the resting as to the desensitized state, whereas thiopental favoured the desensitized state. This means that the structure±activity relationships governing interaction between the barbiturates and their site are different for each conformation. Furthermore, it can be inferred from their potency for inhibiting the open channel that a third set of structure±activity relationships exists for the open state. 16 Although the location of the barbiturate binding site is not known with certainty, a case can be made for it being in the channel lumen. Indeed, a number of agents have been shown to photolabel the receptor in this region. It is located on the central axis of pseudosymmetry, so that all ®ve subunits are exposed to the conduction pathway. Cryoelectron microscopy clearly shows the receptor to change structure here in a state-dependent manner. 67 More recently, studies using 3-(tri¯uoro-methyl)-3-(m-iodophenyl) diazirine (TID), a photoaf®nity ligand that interacts with the channel in the resting state, have been used to construct a model of how barbiturates interact with this site. The authors suggest that the barbiturate pyrimidine ring is located just above the highly conserved M2 9¢ ring of leucines, and that the side chain projects downwards into the lumen of the channel where it encounters varying amounts of steric hindrance depending on the receptor's conform- 2 If this general location is correct, then the allosteric interaction between the barbiturate and the agonist site is transmitted over distances of tens of A Ê ngstroms.
Kinetic studies
Evidence for sites on open channels must come both from kinetic information obtained from electrophysiological data and from biochemical data obtained by very rapid cation ux experiments conducted on a millisecond time scale. The former are summarized in Dilger's article herein. 17 The biochemical data on Torpedo membranes also point to an inhibitory site. 69 First, the Hill coef®cients for inhibition by alkanols longer than hexanol are close to 1, suggesting that a single site or a set of sites of equal af®nity mediate inhibition. Second, the dependence of apparent K i on alkanol chain length is steeper than that of lipid solubility or lipid disordering. Third, inhibitory activity is constrained sterically; only alcohols with molecular volumes below 340 A Ê 3 or above~100 A Ê 3 are able to inhibit the nAcChoR. 70 Whilst this evidence is persuasive, more de®nitive proof is provided by the strategy of exposing the open channel to two anaesthetic agents simultaneously and examining the interactions between them. 71 Essentially, if one agent occupies half the inhibitory sites, the second will then have only half the probability of ®nding an inhibitory site. If, on the other hand, the two agents act on a large site or by dissolving in the lipid bilayer, the presence of one will not interfere with the action of the other. By titrating octanol and heptanol against each other it was possible to show that they acted at distinct sites on the open state of the nAcChoR. This strategy should work for studying the enhancement of inhibitory currents by general anaesthetics but it has rarely been employed. In one example, the interaction between pentobarbital and propofol was examined on the glycine receptor and evidence for mutually exclusive action reported. 51 There are two other interesting features that suggest mechanisms of alcohol action on the acetylcholine receptor.
First, as mentioned, the Hill coef®cients for channel inhibition are 1, but for the smallest alcohols (below hexanol) they become 2 ( Fig. 3) . One might cautiously interpret this to mean that two molecules of the smaller agent might be accommodated in the channel inhibition site. This behaviour is reminiscent of the luciferase binding site, which accommodates two molecules of shorter alcohols but only one of longer ones. At higher concentrations where alcohols stabilize the desensitized state of the acetylcholine receptor, they do so with even higher Hill coef®cients.
Mutagenesis
A popular method for locating these sites of action is sitedirected mutagenesis. This has been employed both on nicotinic and on GABA A /glycine receptors and points, respectively, to a site in the channel lumen (M2) and a site between M1, M2 and M3 (all presumed to be helices). This approach is reviewed elsewhere in this volume. 17 66 Sitedirected mutagenesis is a convenient and useful method. However, it needs to be employed judiciously. The danger should be obvious from the above discussion where slight differences in the structures of barbiturates are suf®cient to change their binding selectivity between states. This re¯ects the fact that the binding pocket changes shape as the conformation changes. Conversely, altering the shape of an amino acid side chain at any cavity that has different geometry in different conformations carries the risk of tipping the free energy balance between the conformations. This could lead to misleading results. For example, if a mutation far from the barbiturate site discussed above favoured the desensitized state, an apparent decrease in amobarbital's binding af®nity would be detected. Only if care were taken to determine independently the effect of the mutation on the resting-to-desensitized equilibrium would one avoid the false conclusion that the mutation was located at the barbiturate site.
In the ligand-gated ion channel superfamily, the anaesthetic sites characterized by site-directed mutagenesis are all near the gating machinery. Mutations at many of these sites alter gating as well as anaesthetic action. 26 37 This Cassandrian view is strengthened by recent studies showing that widespread mutations on the acetylcholine receptor unassociated with any binding site can affect gating. 31 
Photoaf®nity labelling
Whilst the evidence for the sites given above is strong and often self-consistent, structural data are required both to de®nitively prove the existence and to de®ne the location of the sites. Three-dimensional structures are unlikely to be available for some time. A technique that can provide information at the sequence, or primary structure, level is photoaf®nity labelling. It is complementary to site-directed mutagenesis and has been successfully employed to identify the amino acids that form the agonist and local anaesthetic sites on the nAcChoR and the benzodiazepine sites on the The nature of sites of general anaesthetic action GABA A receptor. 19 33 62 Such an approach has been pioneered for general anaesthetics using [
14 C]halothane. 10 21 However, this agent has low radioactive speci®c activity, poorly understood photochemistry and must be photoactivated at~250 nm, a wavelength likely to interact with the target protein. For example, of the seven halothane sites found by crystallography on human serum albumin (HSA), 5 [ 14 C]halothane photolabels only the one of low af®nity. 20 Aromatic diazirines have very good photochemical properties and have been widely applied in other ®elds. 4 7 Recently, a number of alkanols containing diazirine have been characterized. They are unexceptional general anaesthetics that obey the Meyer±Overton rule, enhance GABAinduced currents and inhibit acetylcholine-induced currents. One of them has been synthesized in a tritiated form and used to de®ne sites on the a-subunit of the nAcChoR from Torpedo.
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Anaesthetic sites on the nicotinic acetylcholine receptor
]azioctanol photolabels the nAcChoR selectively at the a-subunit. This is rather reassuring because a priori one might expect a lot of random photoincorporation when the diazirine is activated by shining light at 360 nm onto the sample. In fact, the carbenes so formed are relatively short lived, and often react intramolecularly. Thus, it is only a small fraction of the agent that is incorporated into the protein. Edman degradation techniques were employed to locate the binding sites on the a-subunit. The location of these is indicated by squares on the structural diagram of the subunit structure in Figure 1 . The main site of photoincorporation was at the top of the M2 channel-lining region. A second site was in the lipid±protein interface region of M4, and much lower levels were incorporated in the N-terminal region. 53 We will consider each of these below in order of increasing interest.
Two of the three residues that were identi®ed in M4 are also photolabelled by the extremely hydrophobic photolabel TID, placing them in the lipid±protein interface, but the third appears to occur before the predicted start of M4 and may be on a turn before that helix. This selective labelling of the lipid±protein±water interface region is reminiscent of the situation in the model channel gramicidin. 63 Theoretical mechanisms exist for how such interactions might have functional effects on proteins. 8 These are based on the assumption that a membrane protein's topology changes when its conformation changes and that actions of general anaesthetics on lipid bilayer lateral pressure can therefore change the relative free energy of conformational states. An alternative notion, possibly applicable to steroid anaesthetics, is that anaesthetics bind at speci®c lipid-binding sites in the lipid±protein interface. 12 56 The residues in the N-terminus are known to be in the agonist binding pocket. They can be located on the recent crystal structure of the acetylcholine binding protein and are very close to the subunit±subunit interface, and not far from residues detected by photolabelling with halothane. 10 Photoincorporation was increased 10 fold at the M2 site when agonist was used to desensitize the receptor. At the highest concentrations used, [ 3 H]azioctanol induced desensitization itself, enhancing photoincorporation in the absence of agonist. Some agonist-sensitive binding was also observed on the b-subunit. The residue labelled was aGlu-262, which is on the C-terminal of M2 and 20 amino acids from the charged residue located at the N-terminal of the pore; hence it is referred to as being in the 20¢ position (Fig. 4) . It may seem paradoxical that a charged amino acid is labelled but glutamate also contains two methylene groups, and crystallographic studies show that such interactions are not unusual. 5 The residue photolabelled at the top of the M2 channellining region, aGlu-262, is 10 residues from the ring of small polar 10¢ residues that were the ®rst to be implicated by site-directed mutagenesis in the inhibition of the nAcChoR by alcohols. 26 This alcohol site is now thought to extend from the 8¢ to the 13¢ residues. 73 Separating the 10¢ and 20¢ rings of residues is a stretch of highly hydrophobic residues. A plausible working hypothesis is that the aliphatic tail of 3-azioctanol extends down into this region. This notion may be tested in the future by using azialcohols, such as 7-azioctanol, with the diazirine group further from the hydroxyl.
1 What is clear is that when the third carbon of 3-azioctanol is placed adjacent to the 20¢ position, octanol's aliphatic chain can extend little more than one turn of the helix down into the channel, and certainly not into the 8¢±13¢ region. Thus, either the location 3-azioctanol adopts in the desensitized state is not quite the same as the one it will adopt in the open state, or the mutagenesis is misleading for some reason. Thus, it is desirable to photolabel the nAcChoR in the open state, and methods to achieve this have been developed. 44 
Photolabels as molecular rulers
In a recent study two geometric isomers of octanol bearing a diazirine group on either the third or seventh carbon (3-and 7-azioctanol, respectively) were used to locate and delineate an anaesthetic site on adenylate kinase. 1 This enzyme was chosen for a number of reasons. First, halothane inhibits muscle adenylate kinase, an action once implicated in general-anaesthetic-induced malignant hyperthermia. 58 Second, adenylate kinase's allosteric states have been studied in incredible detail, the structures of many conformations having been determined at high resolution. 68 Adenylate kinase, which photoincorporated both 3-and 7-azioctanol at a molar ratio of 1:1 as determined by mass spectrometry (MS), was subjected to tryptic digest and the fragments separated and sequenced by HPLC/MS/MS. 3-Azioctanol photolabelled His-36, whereas its isomer, 7-azioctanol, photolabelled Asp-41. Inspection of the known structure of adenylate kinase showed that the side chains of these residues are within~5 A Ê of each other. This distance matches the separation of the 3-and 7-positions of an extended aliphatic chain (Fig. 5) . The interpretation is that azioctanol binds its site on adenylate kinase with its aliphatic chain in an extended conformation. 
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All adenylate kinases share a similar three-domain structure (Fig. 5) . They have a central domain (CORE) consisting of a ®ve-stranded parallel b-sheet surrounded by a-helices, an a-helical nucleotide monophosphate binding domain (NMPbind) and a region that covers the active site during catalysis (LID). 68 The alkanol site spans two domains of adenylate kinase. His-36 is part of the CORE domain and Asp-41 belongs to the NMPbind domain. Upon binding the substrate-mimicking inhibitor adenosine-(5¢)-pentaphospho-(5¢)-adenosine (Ap5A), the NMPbind domain rotates relative to the CORE domain, closing up the alkanol binding pocket and reducing the photoincorporation of [ 3 H]3-azioctanol by 75%, consistent with the picture of allosteric action discussed above.
Future directions for photolabelling
Photolabelling techniques are currently providing information about the location of general anaesthetic sites on membrane proteins that cannot be obtained by any other technique. Unfortunately, Edman degradation techniques require milligrams of protein, particularly when the sequences under study are composed of hydrophobic amino acid residues, and the techniques cannot be applied to neuronal ion channels because these express poorly. The The nature of sites of general anaesthetic action latter issue is an important roadblock. Most electrophysiologists are happy with a few channels, and so have not attempted high-level expression of receptors. Even if highlevel expression is achieved, the issue of puri®cation will remain. Thus, a good strategy for photolabelling will be to develop expression systems with higher yield in parallel with exploring more sensitive sequencing techniques. In the latter regard, the use of MS provides many advantages.
Because different classes of general anaesthetic may have different sites, it is important to synthesize diazirine derivatives of volatile and intravenous general anaesthetics. A number of groups are making progress on this, analogues of halothane, 23 etomidate and steroids 13 being in various stages of development.
Nature of anaesthetic binding sites

Nature of sites on proteins
The tools of pharmacology, biochemistry and site-directed mutagenesis have all yielded evidence that points strongly to the existence of general anaesthetic sites on excitable proteins. These proteins are mainly membrane proteins. It turns out to be extraordinarily dif®cult to crystallize membrane proteins, and even when crystallization is achieved the crystals often do not yield structures of the highest resolution. This resolution is necessary if the interactions of small anaesthetic molecules with the proteins' structures are to be resolved in detail. Thus, the best information on general anaesthetic±protein interactions comes from structural studies of soluble proteins, most of which are of no conceivable relevance to general anaesthesia. While one may regret the lack of pharmacological relevance, general principles derived from such model, or surrogate, systems should apply also to membrane proteins.
Protein sites for small molecules
The xenon complex with myoglobin was the ®rst anaesthetic±protein interaction to be characterized in detail. 60 64 At a pressure of 7 bar, one major (almost fully occupied) and three secondary (half-occupied) sites were found. The ®rst site is highly occupied at clinical concentrations. Xenon binds to it with very little perturbation of the surrounding molecular structure. Cyclopropane and dichloromethane have also been shown to bind to the major xenonbinding site in myoglobin but their greater size distorts the surrounding protein structure and causes rearrangement of some amino acid side chains. 59 Crystallographers have long had an interest in xenon because, as a heavy atom, it helps them do the necessarỳ phasing' that is required to solve structures using x-rays. It has been claimed that as many as 40% of proteins have cavities suitable for binding xenon. 39 There is thus a large body of crystallographic data barely mined by anaesthesia researchers. Xenon binds to intramolecular as well as to intermolecular sites, to inaccessible cavities, as well as to exposed pockets and even into channel pores. 52 A cavity is a region in a protein that is not occupied by protein atoms and that is entirely closed off from the surrounding aqueous phase. How do anaesthetics gain access to such cavities deep in the interior of proteins? Analysis of x-ray data indicates that in the interior of proteins, atoms make only small (0.25±0.5 A Ê ) excursions on the picosecond time scale from their mean positions, whereas on the protein's surface the amplitude of such¯uctuations may be several angstroms and they occur on the micro-to millisecond time scale. These¯uctuations allow rapid access of small molecules with a rate constant of 10 6 ±10 7 M ±1 s ±1 , comparable to those at which inhibitors act on neuronal ion channels. In contrast, small molecules access surface-exposed pockets at diffusion limited rates (10 8 ±10 9 M ±1 s ±1 ). 25 Proteins resist forming cavities because of the high free energy cost incurred, so these cavities are probably important for the conformational exibility of proteins, a hypothesis that is supported by the observation of an overall reduction in thermal¯uctuations (x-ray temperature factors) of the protein upon xenon binding, probably caused by a restriction in the number of conformational states.
Intermolecular forces between small molecules and proteins
Intermolecular forces govern the free energy of interaction of general anaesthetics with proteins. The forces experienced inside a protein are complex and vary from location to location on an atomic scale. For example, the pKs of charged amino acids can vary 3-to 4-fold depending on the environment at their location. Consequently, the forces experienced by an anaesthetic are quite complex and are very dif®cult to calculate. Nonetheless, the forces between two isolated uncharged molecules are fairly well understood and provide us with some good rules of thumb. 35 39 65 The interaction energy between two apolar (for example xenon) or dipolar (for example chloroform) molecules decreases (attraction increases) as (1/r 6 ) where r is the separation between them. Often called van der Waal's interactions, they are all electrostatic, essentially dipolar, in origin and consist of dispersion (induced-dipole±induced-dipole), dipole±induced-dipole and dipole±dipole interactions. Dispersion forces arise from the electron clouds orbiting an atom. Although their distribution is uniform when averaged over time, at any moment the non-uniform distribution leaves a small net dipole that will interact with similar dipoles in neighbouring atoms. Dispersion forces tend to predominate. Even in CH 3 Cl, which has a permanent dipole of 1.87 Debye, they provide two-thirds of the interaction energy. The repulsive interaction between two molecules is essentially quantum mechanical in origin. Empirically, it can be described as depending on (1/r 12 ). This is a very steep function of separation approximating a hard sphere interactionÐthe molecules collide much like billiard or snooker balls.
The total intermolecular pair potential w(r), which is the sum of the attractive and repulsive interaction energies, depends on distance as:
where s is the diameter of the molecules and r is the separation of their centres. This is illustrated in Figure 6 . As the two approach, little attraction occurs until their hard sphere surfaces are separated by one diameter (s) or their centres are separated by 2s. The maximum interaction does not occur until the centres are separated by 1.12s. On closer approach, repulsion increases rapidly and the interaction becomes unfavourable as the hard spheres clash. The diameters of a xenon atom and a methane molecule are 4.3 and 4.0 A Ê , respectively, so the strength of the interaction is maximum when they approach to within~0.5 A Ê and is negligible beyond 5 A Ê . The actual size of the interaction will increase with the atom's polarizability, but no emphasis should be put on calculating its absolute magnitude because the situation in a protein pocket is so complex that it might be misleading.
Thus, once in a pocket, an anaesthetic is surrounded by many other atoms with their own instantaneous dipoles competing for attention. The system is no longer additive. Furthermore, the pocket's lining may contain dipolar residues, so the possibility of dipole±dipole or induceddipole±dipole interactions has to be considered. While dipolar interactions average to a (1/r 6 ) dependence when rotating, restricted rotation may lead to longer range interactions with a (1/r 3 ) dependence. For an apolar anaesthetic the longest range interactions that occur are with charged residues (1/r 4 ). Fixed dipole±charge interactions with charged residues have even longer range: a (1/ r 2 ) dependence. These longer range attractive interactions will intersect with the repulsive potential at greater separation of centres, yielding deeper potential energy wells. Furthermore, transfer of a gaseous anaesthetic from the gas phase to a suitable pocket in a protein involves con®ning it in a small space. This always carries a signi®cant entropic cost, roughly the same for all apolar gases, that partially offsets the interaction energy decrease shown in Figure 6 . Dipolar gases may lose the ability to rotate freely, adding further to this entropic cost.
While the situation seems complex, some remarkably robust conclusions can be drawn. First, as Figure 6 shows, all interaction potentials exhibit the same repulsive interaction. When the centres are separated by one diameter (i.e. the spheres are touching), there is no net interaction energy and further approach can only occur at tremendous cost. This means that an anaesthetic will be unable to access a pocket that is too small for it unless that pocket has somē exibility. Second, the maximum attraction does not occur until very close approach is achieved. At this point the separation of the sphere's surfaces are 12 and 20% of a diameter for a (1/r 6 ) and a (1/r 2 ) dependence, respectively. The corresponding half-maximum interactions occur at 40% and 95% of a diameter. Thus, strong interactions require close approach between an anaesthetic and the surrounding amino acid residues. Therefore, by assessing the size of a binding pocket and the polarity of the residues exposed on its surface, reasonable guesses about its ability to interact with anaesthetics can be made. This analysis also suggests why polarity is a useful property of general anaesthetics. Polar anaesthetics can exert favourable interactions over a longer range than can apolar ones and are therefore less dependent on the goodness of ®t in a pocket.
Detailed examination of an internal cavity
The issue of what factors govern binding of small molecules to cavities inside proteins has been systematically examined by Matthews and colleagues. Their studies provide useful insights into the characteristics a site needs if the Meyer±Overton relation is to govern its interaction with small molecules and into the effects of site-directed mutagenesis on binding pockets. The model employed for convenience is the bacteriophage T4 lysozyme. It contains a 
54 Argon, krypton and xenon form a homologous series with the van der Waal's volumes of 29, 35 and 45 A Ê 3 , respectively. All three bind to the large site but not to the smaller sites because the free energy cost of distorting the protein's structure to enlarge the smaller cavities is not repaid by the additional anaesthetic±protein interaction energy. This steric exclusion suggests that only those proteins with large enough preexisting internal cavities will have the potential to bind general anaesthetics. A recent analysis of a randomly selected group of proteins of known structure shows that cavities of 40±50 A Ê 3 are relatively common, whereas cavities the size of more typical general anaesthetics (saỹ 150 A Ê 3 ) occur in some 10±15% of cases. 22 This is a surprisingly large number, and one might ask why general anaesthetics do not have even more side-effects than they do. One explanation is that in many cases the af®nity for general anaesthetics is insuf®cient for signi®cant occupancy to occur under clinical concentrations. Another explanation might be that when binding does occur it does not always result in a change in the protein's function.
In T4 lysozyme, mutation of a leucine residue in the large cavity's wall to the smaller amino acid alanine (L99A mutant) eliminates an isopropyl group and expands that cavity to a volume of 178 A Ê . 3 The dissociation constants of the gases in this enlarged cavity were estimated from partial pressure titrations to be about twice their anaesthetic potencies:`2,~8 and b32 atm for xenon, krypton and argon, respectively. (The anaesthetic partial pressures are 0.95, 4.5 and 18 atm respectively.) The engineered cavity is large enough theoretically to accommodate four xenon atoms with a squeeze, or six argon atoms, but in fact the noble gases are not randomly distributed in the cavity. Instead, they tend to occupy three highly preferred sites that are numbered here in order of decreasing af®nity. Site 1 is created by the mutation, site 2 is essentially the same as in the wild-type site and site 3 is found between sites 1 and 2, giving an approximately collinear arrangement of three equally spaced sites. 54 Sites 1 and 2 are separated by 5.4 A Ê . Even the smallest gas argon has a radius of 1.9 A Ê , precluding binding at the central site when the peripheral sites are occupied. Thus, the average occupancy of site 3 decreases as overall occupancy increases. Simulations indicated that in addition to the favourable binding energy for site 1, the second xenon bound with positive cooperativity to site 2. This was not caused by xenon±xenon interactions because the separation was too great, but it might have resulted from a deformation of site 1 during binding. Such double occupancy of cavities appears to be quite common, being observed for volatile agents in luciferase and HSA (see below). 5 29 Of relevance to more conventional general anaesthetic agents, the entropic cost of con®ning xenon to the site was less unfavourable than in the case of benzene because the latter lost not just its lateral translational freedom but also its freedom to rotate. 39 This suggests that the more polar anaesthetics, which might bene®t from complimentarity in the binding pocket (e.g. alignment of dipoles or orientation of hydrogen bonds), will pay a small entropic penalty relative to less polar agents.
Although, as expected, the binding af®nity increased with the polarizability of the inert gases in the order argon, krypton, xenon, exceptional behaviour was observed in one engineered pocket where krypton exhibited a higher af®nity than xenon. The origin of this effect might be a better ®t of krypton in the pocket and steric exclusion of xenon, but the investigators were unable to rule out long-distance allosteric effects caused by binding at other sites. 54 Nonetheless, the example is salutary because it raises the possibility that not all actions of general anaesthetics need to scale as multiples of anaesthetic potency.
A good test of the ability of the Meyer±Overton relationship to predict binding to such internal cavities was provided by a study of alkylbenzene binding to the L99A mutant of T4 lysozyme. 46 The benzene moiety was found to bind in xenon site 1, whilst site 2 bound the alkylbenzene's side chain. In site 1 the amino acid side chains were rather rigid and therefore capable of discriminating between ligands of different shape. At this site, geometric isomers created by moving methyl and ethyl groups around the benzene ring bound with af®nities that were uncorrelated with their octanol/water partition coef®-cients because the geometric constraints of the site were not modelled by the solvent interactions. In site 2 the amino acid side chains were more deformable, allowing some promiscuity in binding. In one series of compounds where successive methylenes were added to the aliphatic chain of toluene, extending it to n-butyl, binding af®nity did correlate with octanol/water partition coef®cients. However, even here steric factors were important, with tert-butyl side chains being excluded from the site. One may conclude that the best correlations with octanol partitioning are likely to be found in sites that can deform to accommodate a small change in a ligand's size without incurring a high energy cost.
A further factor governing binding was the polarity of the ligand. The cavity in the L99A form of T4 lysozyme was lined with apolar amino acid residues incapable of hydrogen bonding to ligands. The site excluded water and other polar molecules, such as ethanol and even chloroform.
The effects of mutations designed to alter the dimensions of cavities on the protein's structure are of importance to those designing strategies for site-directed mutagenesis. 26 42 One of the issues is whether the mutation alters just the binding properties of the general anaesthetic, as is usually assumed, or whether it also alters the protein's structure, perhaps altering the kinetics governing interconversion between conformational states (e.g. gating) that would have the potential to complicate interpretation. In T4 lysozyme, enlarging a cavity through large-to-small mutations of amino acid residues in the cavity wall caused the protein structure to contract slightly so that the gain in volume was not as large as expected. This implies a change in the overall exibility of the protein, which might affect function. However, binding was little affected because this contraction in cavity volume was reversed upon binding a nonpolar ligand. 3 More signi®cantly, making large cavities requires particular caution. In one of a series of double mutations, an a-helix neighbouring the cavity rearranged into a non-helical structure, collapsing into the cavity and preventing ligand binding.
Clinical general anaesthetics bound to proteins
The number of high-resolution structures containing general anaesthetics of clinical relevance is very limited. So far luciferase has been crystallized only in the conformation that has low af®nity for general anaesthetics, and so HSA provides the highest resolution structures. 5 29 This heartshaped protein contains 585 amino acids organized into three homologous domains (labelled I±III), and each domain consists of two subdomains (A and B) that share common structural elements (Fig. 7) . Its structure was determined to high resolution with either halothane or propofol bound. The smaller halothane bound at eight sites, the larger propofol at only two. All anaesthetic binding sites were preformed pockets or clefts capable of binding fatty acids.
The propofol structure had the higher resolution and its position within the pockets was characterized in some detail. At the highest af®nity site, propofol bound in an apolar pocket on subdomain IIIA of HSA (Fig. 8A) . The phenolic hydroxyl group made a hydrogen bond 3.1 A Ê long with the main peptide chain carbonyl oxygen of Leu-430, and the aromatic ring was sandwiched between the side chains of Leu-453 and Asn-391. Of the two isopropyl Fig 7 The propofol and halothane binding sites on human serum albumin. The structures were determined by x-ray crystallography. 5 The main subdomains are labelled with roman numerals. (A) Both propofol sites are shown. PRO1 and PRO2 are numbered in order of decreasing af®nity. Crystals were grown in the presence of 4 mM propofol in 25% polyethylene glycol. (B) The three halothane sites with highest af®nity, HAL1±3, were observed when the crystals were exposed to 5% halothane (~2.5 mM). Five other sites were observed at a much higher halothane partial pressure (20%). See text and reference 5 for further details. Reproduced with permission. The nature of sites of general anaesthetic action groups, one made numerous apolar contacts in the pocket, whereas the other was partially exposed at the aqueous entrance. The deeper isopropyl group caused the side chain of Val-433 to rotate 120°upon binding, allowing more motion to occur than in the solvent-exposed isopropyl group. The second site differed in having aromatic character. Propofol's aromatic ring makes contact with Leu-532 and Phe-502; its hydroxyl hydrogen bonds to the hydroxyl of Ser-579.
The halothane structure was of lower quality so I will not discuss the orientation of halothane in the binding pockets. A number of features stand out, however. The two halothane sites with highest af®nity were in a solvent-exposed trough (fatty acid binding site 6) at the interface of subdomains IIA and IIB (Fig. 8B) . These pockets were much more polar than those occupied by propofolÐnearly half the residues were charged, the rest were aliphatic. In many cases, halothane interacted with the aliphatic portion of the charged side chains, but in others there were signi®cant polar interactions, particularly with the polarizable bromine atom of halothane.
It has been suggested that propofol has a different site on the GABA A receptor from iso¯urane, which itself shares a site with halothane. 36 38 It is thus of interest that only one of the two propofol sites in HSA bound halothane. Presumably halothane ®nds more cavities because of its smaller size, but the reasons for this selectivity have not been laid out. Nor was it possible to rationalize the relative af®nity of the halothane sites on the basis of their amino acid composition. 5 A question of concentration One of the philosophical issues surrounding the use of x-ray crystallography is the high concentrations of general anaesthetics employed, necessary in order to ensure full occupancy of binding pockets. They would seem to be entirely justi®ed currently because the proteins available to be studied are not of direct pharmacological signi®cance and they are studied to obtain an understanding of protein±anaesthetic interactions. A more dif®cult case will arise when a relevant target is under study. One would expect in such a case that the apparent af®nity of the site will be established by kinetic and pharmacological studies, long before crystallization is successful. These studies will then de®ne the permissible concentrations for crystallization, which will need to be at least 10 times the dissociation constant to approximate saturation. If the dissociation constant is comparable to clinical concentrations (probably a worst-case scenario), would 10 times higher concentrations harm the protein's structure? Probably not because, in the case of HSA, good crystals were obtained up to 2.5 mM halothane (>10 times clinical concentrations), and in the stabilizing presence of fatty acids up to 10.5 mM, a solution which is more than half saturated.
How do general anaesthetics act on proteins?
Binding to a site on a protein at clinical concentrations is not a suf®cient condition for anaesthetic action. The bound agent must interfere with the protein's function in some way. Older theories postulated that anaesthetics unfolded, or denatured, protein structure, but such actions occur at such high concentrations as to be irrelevant.
Allosteric mechanisms were invoked above to account for actions on the ligand-gated ion channel superfamily. The structural basis for these actions is not currently known, although in the case of the channel inhibition site, the central ion pore located at the junction of all ®ve subunits clearly provides a site whose topology must perforce change as the receptor's conformation changes. 9 A similar principle seems to be followed by adenylate kinase where the octanol site spans two domains of the protein that move relative to each other during catalysis. 1 In the case of the putative site between the ®rst, second and third transmembrane segments of the GABA A receptor, the situation is less clear. 32 Anaesthetics inhibit luminescence in both bacterial and ®re¯y luciferase by directly competing with 1-decanal 15 41 and luciferin, 30 respectively, both cofactors that bind to well-de®ned sites. These binding sites accommodate a remarkable range of volatile anaesthetics at clinical concentrations but tend to exclude intravenous agents. Thus, general anaesthetics here interact with rather well-de®ned protein clefts or pockets, displacing a ligand essential for the enzymes' function. Although they may also interact allosterically, and in the case of the ®re¯y luciferase do so, 29 this is not the critical action. In HSA, propofol binds to one of the more important drug binding sites, providing an example of competitive interaction that may be of clinical relevance. 5 Inhibition by competition with a natural ligand has some interesting properties. The apparent potency of an anaesthetic will depend upon the concentration of that ligand, decreasing as the latter increases. Thus, if the concentration of the ligand in a cell depends on the cell's activity, so will the sensitivity of the protein to anaesthetics. For example, at low, but not at high, ligand concentrations, the activity of the protein will be reduced by general anaesthetics competing effectively for the ligand. If the activity of the protein is under independent feedback control, it is possible that the anaesthetic-induced inhibition might be only transitory, being overcome with time as the concentration of ligand is increased. Well-characterized examples of such actions remain to be found however.
Summary
The molecular nature of the site of general anaesthesia has long been sought through the process of comparing the in vivo potencies of general anaesthetics with their physical properties, particularly their ability to dissolve in solvents of various polarities. This approach has led to the conclusion that the site of general anaesthesia is largely apolar but contains a strong polar component. However, there is growing evidence that several physiological targets underlie general anaesthesia, and that different agents may act selectively on subsets of these targets. Consequently research now focuses on the details of general-anaesthetic±-protein interactions. There are large amounts of structural data that identify cavities where anaesthetics bind on soluble proteins that are readily crystallizable. These proteins serve as models, having no role in anaesthesia. Two problems make studies of the more likely targetsÐ excitable membrane proteinsÐdif®cult. One is that they rarely crystallize and the other is that the sites have their highest af®nity for general anaesthetics when the channels are in the open state. Such states rarely exist for more than tens of milliseconds. Crystallographers are making progress with the ®rst problem, whilst anaesthesia researchers have developed a number of strategies for addressing the second. Some of these (kinetic analysis, site-directed mutagenesis) provide indirect evidence for sites and their nature, whilst others seek direct identi®cation of sites by employing newly developed general anaesthetics that are photoaf®nity labels. Such studies on acetylcholine, glycine and GABA receptors point to the existence of sites located within the plane of the membrane either within the ion channel lumen (acetylcholine receptor), or on the outer side of the a-helix lining that lumen (GABA A and glycine receptors). Bound anaesthetics generally exert their actions on ion channels by binding to allosteric sites whose topology varies from one conformation to another, but de®nitive proof for this mechanism remains elusive.
